Abstract:Objective To investigate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of gemifloxacin tablet in healthy Chinese volunteers and to provide evidences for optimal clinical dosing.Methods Twenty volunteers were enrolled in the randomized (1∶1) double-blind study,and divided into administration group and control group.Each group received multiple oral doses of 320 mg of gemifloxacin tablet or placebo.The plasma and urine samples for gemifloxacin were analyzed by igh-performance liquid chromatogram (HPLC)-fluorometric method. The minimum inhibition concentrations (MIC) of gemifloxacin against 190 clinical isolates were determined by broth microdilution method.The fAUC0～24 h/MIC and fCmax/MIC,with target value of 25 and 5,were used as the indices to evaluate PK and PD characteristics of gemifloxacin. The cumulative fraction of response (CFR) of gemifloxacin against each bacterium and the probability of target attainment (PTA) under various MIC level were evaluated using Monte Carlo simulation following multiple administration at steady state.Results The Cmax of gemifloxacin after once-daily oral doses for 7 days were (1.55 ±0.32) μg/mL and (1.57±0.31) μg/mL for the first and last dose,while the AUC0～24 h were (7.91±1.52) and (8.91±1.15) h · μg · mL-1,respectively.The accumulation factor was 1.13±0.05.The time-profile of gemifloxacin could be described using two-compartment model and the half-life of distribution and elimination phase were (0.64 ± 0.17) and (7.10 ± 2.10) h,respectively. The cumulative urinary excretion rates within 24 h of gemifloxacin were 34.83 ％ and 38.95 ％ for the first and the last dose,respectively.PD study showed that the MIC90 of gemifloxacin were 0.25 mg/L and 0.125 mg/L against Streptococcus pneumoniae and Moraxelle catarrhalis,respectively,while the MIC90 was 2 mg/L against Hemophilus influenza. However,most of Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA) were resistant to gemifloxacin ( MIC90 ＞ 32mg/L).The PTA values of fAUC0～24 h/MIC and fCmax/MIC of gemifloxacin 320 mg daily for 7 days were close to 100％ when MIC was ≤0.06 mg/L.Conclusions Gemifloxacin is rapidly absorbed after oral administration of single doses in healthy Chinese volunteers,and the plasma concentration could reach steady state at the third day,while a minimal accumulation is shown after consecutive 7 days dosing.The PK/PD analysis suggests that the favorable clinical and bacteriological efficacy could be obtained when using this regimen in treatment of sensitive patients with community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease.

Pharmacokinetic and pharmacodynamic study of chinfloxacin hydrochloride in Chinese adult healthy subjects

Pharmacokinetic-pharmacodynamic Modeling of the Antitumor Effect of TM208 and EGFR-TKI Resistance in Human Breast Cancer Xenograft Mice

Inhibition of EGFR Autophosphorylation Plays an Important Role in the Anti-Breast Cancer Efficacy of the Dithiocarbamate Derivative TM208

A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers

Intratumoral Estrogen Sulfotransferase Induction Contributes to the Anti-Breast Cancer Effects of the Dithiocarbamate Derivative TM208.

Enhanced Antitumor Effect of TM208 in Combination with 5-Fluorouracil in H22 Transplanted Mice

Pharmacokinetics/pharmacodynamics of Antofloxacin Hydrochloride in a Neutropenic Murine Thigh Model Ofstaphylococcus Aureusinfection

Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancer

Safety, Pharmacokinetics, and Preliminary Activity of CDK4/6 Inhibitor FCN-437c in Chinese Female Patients with HR+HER2- Advanced Breast Cancer (ABC) From Phase Ia Study

Pharmacokinetic and pharmacodynamic analysis of flomoxef against the clinical isolates of strains

Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients

Pharmacokinetics and pharmacodynamics of intravenous delafloxacin in healthy subjects: model-based dose optimization

In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin Against Escherichia Coli in a Neutropenic Murine Thigh Infection Model.

Effect of TM208 on QGY-7703 xenograft tumor growth.

[Experimental chemo- and chemoendocrine therapy of human breast carcinomas serially transplanted into nude mice]

LC and LC–MS Study of the Bioavailability and Metabolites of TM208 after Oral and Intravenous Administration to Rat

In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin Against Klebsiella Pneumoniae in a Neutropenic Murine Lung Infection Model.

Clinical pharmacokinetics and pharmacodynamics of gemifloxacin in healthy Chinese volunteers following multiple oral administration

Tolerability and Pharmacokinetics of Antofloxacin Hydrochloride after Multiple Oral Dose Administration in Healthy Chinese Male Volunteers.

Preparation and Rats' Pharmacokinetics of TM208 HP-β-CD Inclusion Complexes

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers